Strategic Initiative

Slingshot members are tracking this corporate initiative:

AstraZeneca (AZN) strikes collaboration worth $6.9B to sell and develop Daiichi Sankyo's (DSNKY) HER2-targeting antibody-drug conjugate, Trastuzumab deruxtecan

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details
Shares in Daiichi surged 16% in Tokyo on news of the deal, which AstraZeneca will partly fund through a $3.5B share sale and $1.35B upfront payment.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Mar 29, 2019
Projected Implementation:
Q1, 2019
Relevance Tracked Until:
Q3, 2019
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Trastuzumab Deruxtecan, Her2